BioAtla BCAB
OTC BCAB
$1.50 -0.10 (-6.25%)
At close: Sep 29, 2026 · 4:00 PM EDT

BioAtla (BCAB) EBIT Margin (2020 - 2026)

Updated

BioAtla (BCAB) recorded EBIT Margin of 3.49% in Q2 2026.

Analysis

BioAtla (BCAB) EBIT Margin (2020 - 2026) Analysis & Trends

On a TTM basis, BioAtla's EBIT Margin came in at -377.94% as of Jun 30, 2026, up 201.83 percentage points year-over-year; for FY2025, it was -2965.25%, down 2293.04 percentage points from FY2024.

  • Annual EBIT Margin has a five-year change of +4050.83 percentage points (FY2020 to FY2025).
  • Across earlier years, EBIT Margin came in at -672.21% in FY2024 and -38576.00% in FY2021 (-31559.92 pp).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 28.21%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 37.86%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -3.52%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 32.97%
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 20.57%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 34.95%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 37.40%
10 BioAtla 2.49 Mn 2.49 Mn - 3.49%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.49%
Dec 31, 2025 -462.75%
Sep 30, 2024 -102.45%
Jun 30, 2021 -12,184.00%
Sep 30, 2020 -5,343.33%
Jun 30, 2020 -2,378.95%
Mar 31, 2020 -1,246.07%
API Access

BioAtla EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=BCAB&period=max&api_key=YOUR_API_KEY